


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Moore et al.

Application Serial No.: 09/376,430

Filed: August 18, 1999

For: **Cytokine Receptor Common
Gamma Chain Like**



Art Unit: 1646

Examiner: O'Hara, E.

Attorney Docket No.: PF466P1

14/B
P. 93
1/13/01

RESPONSE AND AMENDMENT UNDER 37 C.F.R. § 1.111 TO PAPER NO. 11

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action dated 6 July 2000, (Paper No. 11), applicants hereby request that the following amendments and remarks be entered into the above-identified application. Submitted concurrently herewith is: (a) a Fee Transmittal; (b) a Petition for Extension of Time for a period of three months, up to and including January 6, 2001; (c) a Supplemental Information Disclosure Statement and Form PTO/SB/08A; and (d) Appendix A (claims in compliance with 37 C.F.R. § 1.121(c)(1)(i)). Please amend the application as follows.

In the Claims:

Please cancel claims 1, 13, 17-19, 22 and 23 without prejudice.

Please amend the claims as follows:

38. (Once amended) An isolated heterodimer comprising the isolated polypeptide of claim 24.